FDA Determines Regulatory Review Period for BARHEMSYS Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for BARHEMSYS, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO). The FDA is publishing this notice as required by law.